Sara R Vazquez

Summary

Affiliation: University of Utah
Country: USA

Publications

  1. doi request reprint Advances in the diagnosis and management of postthrombotic syndrome
    Sara R Vazquez
    University of Utah Health Care Thrombosis Service, Salt Lake City, UT 84132, USA
    Best Pract Res Clin Haematol 25:391-402. 2012
  2. pmc Azathioprine-induced warfarin resistance
    Sara R Vazquez
    UDepartment of Pharmacy Services, University Thrombosis Service, University of Utah, Salt Lake City, UT 84108, USA
    Ann Pharmacother 42:1118-23. 2008
  3. pmc Contemporary issues in the prevention and management of postthrombotic syndrome
    Sara R Vazquez
    University of Utah Thrombosis Service, Department of Pharmacy Services, University of Utah, Salt Lake City, UT, USA
    Ann Pharmacother 43:1824-35. 2009
  4. pmc Peri-procedural anticoagulation in patients undergoing ablation for atrial fibrillation
    Sara R Vazquez
    University of Utah Thrombosis Service, University of Utah, Department of Pharmacy Services, 675 Arapeen Drive, Suite 100, Salt Lake City, UT 84108, USA
    Thromb Res 126:e69-77. 2010
  5. doi request reprint Anticoagulation clinic workflow analysis
    Sara R Vazquez
    University Thrombosis Center, College of Pharmacy, University of Utah, Salt Lake City, UT 84108, USA
    J Am Pharm Assoc (2003) 49:78-85. 2009
  6. doi request reprint Current challenges in personalizing warfarin therapy
    Gwendolyn A McMillin
    Department of Pathology, University of Utah, ARUP Laboratories, UT, USA
    Expert Rev Clin Pharmacol 4:349-62. 2011

Detail Information

Publications6

  1. doi request reprint Advances in the diagnosis and management of postthrombotic syndrome
    Sara R Vazquez
    University of Utah Health Care Thrombosis Service, Salt Lake City, UT 84132, USA
    Best Pract Res Clin Haematol 25:391-402. 2012
    ..Ongoing clinical trials should provide insight on risk factors, and interventions for PTS prevention and treatment. In particular, use of early thrombolysis for acute iliofemoral DVT to prevent PTS is currently being investigated...
  2. pmc Azathioprine-induced warfarin resistance
    Sara R Vazquez
    UDepartment of Pharmacy Services, University Thrombosis Service, University of Utah, Salt Lake City, UT 84108, USA
    Ann Pharmacother 42:1118-23. 2008
    ..To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction...
  3. pmc Contemporary issues in the prevention and management of postthrombotic syndrome
    Sara R Vazquez
    University of Utah Thrombosis Service, Department of Pharmacy Services, University of Utah, Salt Lake City, UT, USA
    Ann Pharmacother 43:1824-35. 2009
    ..To provide an evidence-based review and clinical summary of postthrombotic syndrome (PTS)...
  4. pmc Peri-procedural anticoagulation in patients undergoing ablation for atrial fibrillation
    Sara R Vazquez
    University of Utah Thrombosis Service, University of Utah, Department of Pharmacy Services, 675 Arapeen Drive, Suite 100, Salt Lake City, UT 84108, USA
    Thromb Res 126:e69-77. 2010
    ..In accordance with national guidelines, warfarin should be continued post-ablation for a minimum of 2 months and then indefinitely in patients with a CHADS(2) score >or= 2...
  5. doi request reprint Anticoagulation clinic workflow analysis
    Sara R Vazquez
    University Thrombosis Center, College of Pharmacy, University of Utah, Salt Lake City, UT 84108, USA
    J Am Pharm Assoc (2003) 49:78-85. 2009
    ..To evaluate a workflow model and define factors affecting patient visit length in an anticoagulation clinic primarily treating an urban patient population...
  6. doi request reprint Current challenges in personalizing warfarin therapy
    Gwendolyn A McMillin
    Department of Pathology, University of Utah, ARUP Laboratories, UT, USA
    Expert Rev Clin Pharmacol 4:349-62. 2011
    ..Through further investigative work, allowing these personalized strategies to realize their full potential, warfarin may remain a preferred therapeutic oral anticoagulant for years to come...